TSVT 2seventy bio
- 4.380
- -0.055-1.24%
- 4.380
- 0.0000.00%
2seventy bio News
Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability
2seventy Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), 2seventy Bio (TSVT) and Marinus (MRNS)
Leerink Partners Sticks to Their Buy Rating for 2seventy Bio (TSVT)
2seventy Bio Analyst Ratings
Positive Outlook for 2seventy Bio's ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics
Buy Rating and High Risk for 2seventy Bio: FDA Approval and Market Expansion Fuel Optimistic Outlook
2seventy Bio Analyst Ratings
TD Cowen Sticks to Its Hold Rating for 2seventy Bio (TSVT)
Analysts Are Bullish on These Healthcare Stocks: 2seventy Bio (TSVT), Immuneering (IMRX)
TD Cowen Sticks to Their Hold Rating for 2seventy Bio (TSVT)
Optimistic Outlook for 2seventy Bio's ABECMA Ahead of FDA Panel Review: A Buy Rating Justified
Buy Rating Affirmed for 2seventy Bio on FDA Meeting and Strong Financial Outlook
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy Bio (TSVT)
Buy Rating Affirmed for 2seventy Bio Amidst Revenue Stabilization and Strategic Growth Initiatives
2seventy Bio Analyst Ratings
Hold Rating for 2seventy Bio Amid Regulatory Risks and Potential Upsides: An Analysis on KarMMa-3 Study Outcomes and Stock Performance
2seventy Bio Analyst Ratings
Samantha Semenkow Maintains Buy Rating for 2seventy Bio Amidst Abecma Revenue Growth Projections and Adjustment in 3L+ MM Forecasts
Daina Graybosch Maintains 'Hold' Rating for 2seventy Bio Amid Revenue Decline and Market Challenges
Analysis
Price Target
No Data
